title: ALK inhibitor has high response in patients with NSCLC.
authors.forename: Deborah
authors.initials: D
authors.lastname: McBride
mesh_terms: D030301:Activin Receptors, Type II / Q000037:antagonists & inhibitors* / Q000235:genetics; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; C425364:ACVRL1 protein, human; D030301:Activin Receptors, Type II